There was no statistically significant difference in the outcome of the two dosing schedules. Eleven patients achieved an undetectable HCV viral load and six had sustained viral response. Three patients discontinued PEG-IFN alpha because of adverse effects, which included severe depression, pancreatitis,...
Amgen has been a pioneer in developing and delivering G-CSF therapy and launched NEUPOGEN in 1991.1 Structure and pharmacokinetics Human G-CSF produced by recombinant DNA technology2 Elimination half-life: approximately 3.5 hours2 Clearance Primarily renal clearance3 Dosing Daily G-CSF injections2 ...
Conclusion The hematopoietic growth factor G-CSF is likely to soon become an integral part of various oncologic and other therapeutic regimens. As part of chemotherapy protocols, G-CSF is capable of reducing neutropenia and facilitating compliance with recommended dosing regimens. ...
Dosing & Uses AdultPediatric Dosage Forms & Strengths injectable solution, single-dose vials Neupogen, Nivestym, Releuko, Zarxio 300mcg/mL 480mcg/1.6mL injectable solution, prefilled syringe for SC Neupogen, Nivestym, Nypozi, Releuko, Zarxio ...
G-CSF therapy was associated with a general trend toward fewer neonatal complications in newborns, as well as a lower rate of serious maternal complications, according to Boxer. His recommendations for dosing depend on the subcategory...
Despite of the utilization of several datasets comprising different G-CSF dosing and timing schedules with and without chemotherapy, there remained a large uncertainty regarding parameter estimates, and consequently, the current parameter settings must be considered as preliminary. This is especially true ...
The dosing scheme used corresponded to that published by Garg et al.15 which was chosen based on its superior efficacy over a shorter treatment duration applied by Duan et al.16 Further randomized efficacy trials were not available at the time of trial preparation. Injections were performed at ...
(LDAC; 10 mg/kg), to mirror exposures reported in the clinic33and combined it with intermittent dosing of the CHK1i, to marked benefit. While our results broadly confirm and extend conclusions reached by other groups using AML cell lines21,23,24,34, we have used patient-derived samples...
(PK/PD) study was conducted to establish the effect of different G-CSF regimens on neutropenia’s incidence for patients treated by eribulin, to proposean optimal G-CSF dosing schedule.Methods: A semi-physiological population PK/PD neutropoiesis model was developedfrom absolute neutrophil counts (...
8 With daily G-CSF dosing at pharmacologic levels, almost all patients with SCN respond with improved ANC values and a reduced incidence of infections and hospitalizations. The Severe Chronic Neutropenia International Registry (SCNIR) was established to monitor the course of SCN and related disorders...